What do systematic reviews say?

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists (spironolactone or eplerenone) probably leads to lower cardiovascular and cerebrovascular morbidity compared with control (placebo or standard care) (moderate certainty).

• Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
  RR 0.38 [0.18, 0.76]
  3 studies · 328 participants
  Moderate

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists (spironolactone or eplerenone) showed no clear difference in hyperkalaemia compared with control (placebo or standard care) (low certainty).

• Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
  RR 1.41 [0.72, 2.78]
  9 studies · 981 participants
  Low

Aldosterone antagonists vs placebo or usual care

Aldosterone antagonists (spironolactone or eplerenone) probably leads to higher gynaecomastia compared with control (placebo or standard care) (moderate certainty).

• Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
  RR 5.95 [1.93, 18.28]
  4 studies · 768 participants
  Moderate

Aldosterone antagonists vs placebo or usual care

• Aldosterone antagonists for people with chronic kidney disease requiring dialysis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 562 participants
  Low

Acetazolamide vs spironolactone 100 mg

Acetazolamide may leads to lower risk of acute mountain sickness compared with spironolactone (low certainty).

• Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
  RR 0.36 [0.18, 0.7]
  1 study · 232 participants
  Low

Acetazolamide vs spironolactone 100 mg

• Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 232 participants
  Low

Acetazolamide vs spironolactone 100 mg

• Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 232 participants
  Low

Acetazolamide vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for preventing high altitude illness: Part 2. Less commonly‐used drugs 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Flutamide 250 mg once to b.i.d. showed no clear difference in participant‐reported improvement of hirsutism 4‐point Likert scale compared with spironolactone 100 mg (low certainty).

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  RR 2 [0.88, 4.54]
  1 study · 20 participants
  Low

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 40 participants
  Low

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 40 participants
  Very low

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 40 participants
  Moderate

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Finasteride 5 mg vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 34 participants
  Low

Finasteride 5 mg vs spironolactone 100 mg

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Finasteride 5 mg vs spironolactone 100 mg

Finasteride 5 mg showed no clear difference in proportion of participants who reported an adverse event compared with spironolactone 100 mg (moderate certainty).

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  RR 0.2 [0.03, 1.41]
  1 study · 20 participants
  Moderate

Finasteride 5 mg vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 34 participants
  Low

Finasteride 5 mg vs spironolactone 100 mg

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 34 participants
  Low